FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2615706081> ?p ?o ?g. }

• W2615706081 endingPage "1377" @default.
• W2615706081 startingPage "1368" @default.
• W2615706081 abstract "Despite persistence of leukemic stem cells, patients with chronic myeloid leukemia who achieve and maintain deep molecular responses may successfully stop the tyrosine kinase inhibitor imatinib. However, questions remain unanswered regarding the biological basis of molecular relapse after imatinib cessation. In IMMUNOSTIM, we monitored 51 patients from the French Stop IMatinib trial for peripheral blood T cells and natural killer cells. Molecular relapse-free survival at 24 months was 45.1% (95% CI: 31.44%–58.75%). At the time of imatinib discontinuation, non-relapsing patients had significantly higher numbers of natural killer cells of the cytotoxic CD56dim subset than had relapsing patients, while CD56bright natural killer cells, T cells and their subsets did not differ significantly. Furthermore, the CD56dim natural killer-cell count was an independent prognostic factor of molecular-relapse free survival in a multivariate analysis. However, expression of natural killer-cell activating receptors, BCR-ABL1+ leukemia cell line K562-specific degranulation and cytokine-induced interferon-gamma secretion were decreased in non-relapsing and relapsing patients as compared with healthy individuals. After imatinib cessation, the natural killer-cell count increased significantly and stayed higher in non-relapsing patients than in relapsing patients, while receptor expression and functional properties remained unchanged. Altogether, our results suggest that natural killer cells may play a role in controlling leukemia-initiating cells at the origin of relapse after imatinib cessation, provided that these cells are numerous enough to compensate for their functional defects. Further research will decipher mechanisms underlying functional differences between natural killer cells from patients and healthy individuals and evaluate the potential interest of immunostimulatory approaches in tyrosine kinase inhibitor discontinuation strategies. (ClinicalTrial.gov Identifier NCT00478985)" @default.
• W2615706081 created "2017-05-26" @default.
• W2615706081 creator A5000888675 @default.
• W2615706081 creator A5004066423 @default.
• W2615706081 creator A5007283971 @default.
• W2615706081 creator A5016240673 @default.
• W2615706081 creator A5022842438 @default.
• W2615706081 creator A5041434329 @default.
• W2615706081 creator A5048325273 @default.
• W2615706081 creator A5050755416 @default.
• W2615706081 creator A5050855608 @default.
• W2615706081 creator A5051984074 @default.
• W2615706081 creator A5052564121 @default.
• W2615706081 creator A5055166871 @default.
• W2615706081 creator A5055797334 @default.
• W2615706081 creator A5068342352 @default.
• W2615706081 creator A5070207000 @default.
• W2615706081 creator A5071449715 @default.
• W2615706081 creator A5075844368 @default.
• W2615706081 creator A5077014294 @default.
• W2615706081 creator A5079181777 @default.
• W2615706081 creator A5085656105 @default.
• W2615706081 date "2017-05-18" @default.
• W2615706081 modified "2023-10-16" @default.
• W2615706081 title "Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study" @default.
• W2615706081 cites W15742580 @default.
• W2615706081 cites W1827459324 @default.
• W2615706081 cites W183737772 @default.
• W2615706081 cites W1968747503 @default.
• W2615706081 cites W1970563382 @default.
• W2615706081 cites W1976194065 @default.
• W2615706081 cites W1978613923 @default.
• W2615706081 cites W1982937478 @default.
• W2615706081 cites W1985444402 @default.
• W2615706081 cites W1989159076 @default.
• W2615706081 cites W1994424250 @default.
• W2615706081 cites W1998406030 @default.
• W2615706081 cites W2014349052 @default.
• W2615706081 cites W2019109464 @default.
• W2615706081 cites W2021642163 @default.
• W2615706081 cites W2022069273 @default.
• W2615706081 cites W2036987278 @default.
• W2615706081 cites W2050752994 @default.
• W2615706081 cites W2053441255 @default.
• W2615706081 cites W2057625089 @default.
• W2615706081 cites W2064367288 @default.
• W2615706081 cites W2065599137 @default.
• W2615706081 cites W2076869962 @default.
• W2615706081 cites W2092349279 @default.
• W2615706081 cites W2107268345 @default.
• W2615706081 cites W2110232771 @default.
• W2615706081 cites W2112817157 @default.
• W2615706081 cites W2117269475 @default.
• W2615706081 cites W2117356576 @default.
• W2615706081 cites W2120126484 @default.
• W2615706081 cites W2122224021 @default.
• W2615706081 cites W2131841032 @default.
• W2615706081 cites W2139945656 @default.
• W2615706081 cites W2141675109 @default.
• W2615706081 cites W2154030078 @default.
• W2615706081 cites W2159649486 @default.
• W2615706081 cites W2160811827 @default.
• W2615706081 cites W2162947108 @default.
• W2615706081 cites W2167325977 @default.
• W2615706081 cites W2167689229 @default.
• W2615706081 cites W2189113171 @default.
• W2615706081 cites W2194645485 @default.
• W2615706081 cites W2278657325 @default.
• W2615706081 cites W2312894731 @default.
• W2615706081 cites W2313607879 @default.
• W2615706081 cites W2345930365 @default.
• W2615706081 cites W2347071589 @default.
• W2615706081 cites W2528188718 @default.
• W2615706081 cites W2557854027 @default.
• W2615706081 cites W307339191 @default.
• W2615706081 doi "https://doi.org/10.3324/haematol.2017.165001" @default.
• W2615706081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6643734" @default.
• W2615706081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28522576" @default.
• W2615706081 hasPublicationYear "2017" @default.
• W2615706081 type Work @default.
• W2615706081 sameAs 2615706081 @default.
• W2615706081 citedByCount "108" @default.
• W2615706081 countsByYear W26157060812017 @default.
• W2615706081 countsByYear W26157060812018 @default.
• W2615706081 countsByYear W26157060812019 @default.
• W2615706081 countsByYear W26157060812020 @default.
• W2615706081 countsByYear W26157060812021 @default.
• W2615706081 countsByYear W26157060812022 @default.
• W2615706081 countsByYear W26157060812023 @default.
• W2615706081 crossrefType "journal-article" @default.
• W2615706081 hasAuthorship W2615706081A5000888675 @default.
• W2615706081 hasAuthorship W2615706081A5004066423 @default.
• W2615706081 hasAuthorship W2615706081A5007283971 @default.
• W2615706081 hasAuthorship W2615706081A5016240673 @default.
• W2615706081 hasAuthorship W2615706081A5022842438 @default.
• W2615706081 hasAuthorship W2615706081A5041434329 @default.
• W2615706081 hasAuthorship W2615706081A5048325273 @default.
• W2615706081 hasAuthorship W2615706081A5050755416 @default.

• next